Clinical study of Leizumab injection-assisted LPI surgery in the treatment of angle closure glaucoma
Objective To observe the clinical effect of the combination of Leizumab injection and laser peripheral iridoplasty(LPL)in the treatment of angle closure glaucoma.Methods This study is a prospective study.One hundred and twelve patients with angle closure glaucoma admitted to our hospital between January 2021 and June 2023 were selected as the study subjects.Based on a randomized and controlled principle,they were divided into a conventional group(56 cases)and a combination group(56 cases)using the computer grouping method.Both groups received LPL treatment,while the combination group received adjuvant treatment with ranibizumab injection.The anterior chamber parameters and anterior peripheral depth,intraocular neovascularization parameters,intraocular pressure,visual acuity recovery,and incidence of adverse events of the two groups were compared.Results Under different treatment regimens,the central anterior chamber depth(CACD),angle of anterior chamber(ACA),and anterior chamber volume(ACV)of the combination group were(1.95±0.27)mm,(26±5)mm,and(85±10)mm3,which were higher than those in the conventional group[(1.52±0.31)mm,(22±5)mm,and(80±10)mm3].The depth of the upper anterior chamber,lower anterior chamber,and nasal anterior chamber in the combined group were(1.15±0.25)mm,(1.36±0.27)mm,and(1.13±0.33)mm.which were higher than those in the conventional group[(0.88±0.42)mm,(0.95±0.31)mm,and(0.92±0.31)mm].Tumor necrosis factor(TNF)-α、interleukin(IL)-1 and vascular endothelial growth factor(VEGF)of the joint group were(30±5)ng/ml,(105±20)pg/ml,and(85±10)pg/ml,which were lower than those in the conventional group[(33±5)ng/ml,(120±21)pg/ml,and(90±10)pg/ml].After 1 month and 3 months of treatment,the intraocular pressure in the combination group was(20±5)mmHg and(15±3)mmHg,which were lower than those in the conventional group[(23±5)mmHg and(18±4)mmHg].The visual acuity was(4.28±1.24)and(4.92±1.46),which were higher than those in the conventional group[(3.81±0.82)and(4.33±1.21)].The incidence of adverse events in the combined group was 7.1％(4/56),which was lower than that in the con-ventional group 23.2％(13/56)(P＜0.05).Conclusion The injection of ranibizumab as an adjunct to LPL surgery can further improve the anterior chamber structure of patients with angle closure glaucoma,which has a positive significance in inhibiting intraocular neovascularization,promoting intraocular pressure and visual recovery,and reducing the risk of adverse events.
NETL
NSTL
万方数据
